Interventional Studies
What are Clinical Trials?
Clinical trials are studies that test new medications in people. Doctors use clinical trials to discover new treatments for diseases. New treatments are possible only through the voluntary participation of patients and family members. Research and Clinical Trials opportunities may be available.
SUVEN
Study Title: SUVEN-502 Study
Purpose:
Individuals with Alzheimer's Disease are invited to participate in SUVEN-502 to determine the effectiveness of oral masupirdine, a medication targeting the serotonin system, and its ability to treat agitation associated with dementia of the Alzheimer's type compared to oral placebo. The study is 20 weeks long. In total, there will be 7 visits. Subjects will receive psychosocial support, undergo medical history, questionnaires/interviews related to agitation symptoms, cognitive assessments in addition to taking the oral medication and medication monitoring. Subjects will also need a study partner to participate in the study with them throughout the entire study.
(Principal Investigator: Pauline Wu, DO, Easton Center’s Katherine and Benjamin Kagan Alzheimer’s Disease Treatment Development Program)
Contact: Lorena Macias at (310) 794-6191 or send an email to LorenaMacias@mednet.ucla.edu to participate in this study or for more information.
More information on the SUVEN study is available at clinicaltrials.gov ID#: NCT05397639.
[18F]PI-2620 Phase 3 Histopathological Study
Study Title: An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance).
Purpose
In this investigation, the drug [18F]PI-2620 is being tested for its usefulness in medical imaging studies to help look for a type of protein in the brain, called tau. [18F]PI-2620 is a compound with a low level of radioactivity attached, for use with positron emission tomography (PET), a type of medical test that resembles getting a CT or CAT scan. PET scanning enables us to see the presence, amounts and locations of certain types of molecules in the brain, and [18F]PI-2620 is being tested for its safety and accuracy in identifying and locating tau molecules. During this study participants will be asked to attend a screening visit to assess their health before receiving an injection of a small amount of [18F]PI-2620, a brain scan for 30 minutes, starting 45 minutes after receiving [18F]PI-2620, and a safety follow up phone call 7 days after the brain scan. Additionally, if any participants die in the months or years after undergoing the scan, their brain tissue will be autopsied and analyzed for presence, location and amounts of protein it may contain so that it can be compared to the PET scan results.
(PI: Daniel Silverman, MD, PhD)
Contact: Dr. Daniel Silverman at (310) 794-5067 to participate or for more information.
More information on the [18F]PI-2620 Phase 3 Histopathological study is available at clinicaltrials.gov ID#: NCT05641688.
LIFUP-MCIAD
Study Title: Modulating Memory with Low-Intensity Focused Ultrasound
Purpose
This clinical trial is sponsored by the National Institute on Aging and aims to assess the ability of low-intensity focused ultrasound pulsation (LIFUP) to affect the brain and potentially improve memory. We are recruiting individuals ages 50-90 with diagnosed or suspected mild cognitive impairment or mild Alzheimer’s Disease. Participation in the study involves receiving brain stimulation with LIFUP and completing memory tests, brain MRI scans, and a blood draw.
(PI: Taylor Kuhn, PhD, ABPP/CN)
Contact: Email tfus@mednet.ucla.edu to participate or for more information.
More information on the LIFUP-MCIAD study is available at clinicaltrials.gov ID#: NCT05417555.